| 
      
        |  |  | N   = 41 | % |  
        | Age at diagnosis | Median age | 58 |  |  
        | Range | 35-77 |  |  
        | Sex | Male | 29 | 71 |  
        | Female | 12 | 29 |  
        | ISS | I | 16 | 39 |  
        | II | 12 | 29 |  
        | III | 13 | 32 |  
        | Immunoglobulin isotype | IgG | 24 | 59 |  
        | IgA | 5 | 12 |  
        | IgM | 3 | 7 |  
        | LC | 9 | 22 |  
        | Karyotype | Normal | 8 | 20 |  
        | Aberrant | 28 | 68 |  
        | Not reported | 5 | 12 |  
        | Cytogenetic risk group (by FISH) | High risk* | 9 | 22 |  
        | Standard risk | 27 | 66 |  | 
  
    | N: Number of Patients; ISS: International Staging System; LC: Light chain
      myeloma; FISH: Fluorescence In-Situ Hybridization. *High risk cytogenetics
    defined as t(4;14), t(14;16) and/or del17p | 
  
    | Table 1: Clinical data and disease characteristics of the patients. |